Prescrire Int. 2004 Feb;13(69):22-5.
(1) The first-line drugs for mild to moderate pain are non opiate analgesics, namely paracetamol and nonsteroidal antiinflammatory drugs (NSAIDs). (2) Codeine, dextropropoxyphene and tramadol are weak opiates; they are often used with paracetamol in fixed-dose combinations, in order to reinforce the analgesic effect of paracetamol. (3) These analgesic combinations have only been evaluated in a few situations associated with chronic and acute pain. And the endpoints used in clinical trials are designed more to show statistically significant differences than clear clinical differences. (4) In acute pain, available meta-analyses confirm that the first-line drug is paracetamol, or, if necessary, ibuprofen, a NSAID. (5) The paracetamol + codeine combination slightly increases the analgesic effect of paracetamol, but causes more adverse effects. Combinations of paracetamol + dextropropoxyphene and paracetamol + tramadol are even less useful. (6) The few available clinical trials fail to demonstrate that combining paracetamol with a NSAID is any more effective than either drug given alone, while adverse effects are increased. (7) Paracetamol is also the first-line treatment for chronic non cancer pain, such as low back pain or pain due to osteoarthritis of the hip. NSAIDs have no advantages over paracetamol in these settings. We found no trials of paracetamol + NSAID combinations. Combinations of paracetamol and weak opiates have been inadequately studied in this situation, and are only second-line options.
(1) 用于轻至中度疼痛的一线药物是非阿片类镇痛药,即对乙酰氨基酚和非甾体抗炎药(NSAIDs)。(2) 可待因、右丙氧芬和曲马多是弱阿片类药物;它们常与对乙酰氨基酚以固定剂量组合使用,以增强对乙酰氨基酚的镇痛效果。(3) 这些镇痛组合仅在少数与慢性和急性疼痛相关的情况下进行了评估。而且临床试验中使用的终点更多是为了显示统计学上的显著差异,而非明显的临床差异。(4) 在急性疼痛中,现有的荟萃分析证实一线药物是对乙酰氨基酚,必要时可使用布洛芬(一种NSAID)。(5) 对乙酰氨基酚 + 可待因组合略微增强了对乙酰氨基酚的镇痛效果,但会导致更多不良反应。对乙酰氨基酚 + 右丙氧芬和对乙酰氨基酚 + 曲马多的组合效果更差。(6) 现有的少数临床试验未能证明将对乙酰氨基酚与NSAID联合使用比单独使用任何一种药物更有效,同时不良反应会增加。(7) 对乙酰氨基酚也是慢性非癌性疼痛(如腰痛或髋部骨关节炎引起的疼痛)的一线治疗药物。在这些情况下,NSAIDs相对于对乙酰氨基酚并无优势。我们未找到对乙酰氨基酚 + NSAID组合的试验。对乙酰氨基酚与弱阿片类药物的组合在这种情况下研究不足,仅为二线选择。